Xcout Intel
Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company based in Toronto, Canada, focused on creating optimized, patentable next-generation psychedelic medicines.
Subscribe to see Mindset Pharma Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Mindset Pharma Inc. at a glance
Mindset Pharma Inc. is a pharmaceuticals company headquartered in Canada. It has raised at least $694,347 across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round raised $694,347 in April 2021. Xcout tracks 4 named people at Mindset Pharma Inc., including James Lanthier (CEO).
Mindset Pharma Inc. leadership
- James LanthierCEO
- Makoto Inouepresident and representative director
- Jill RomanDirector, External Communications
- Jeffrey GilbertLeader, Pharmaceutical PR
Mindset Pharma Inc. funding rounds
At least $694,347 raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $694,347 | — | |
| Seed | Undisclosed | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Mindset Pharma Inc. competitors
A few of Mindset Pharma Inc.'s closest competitors — see the full list of competitors and alternatives →
Denovo Sciences Inc. is an AI-driven drug discovery company developing proprietary technologies and automated systems for early-stage small-molecule discovery and single-cell analysis. The company has collaborated with international partners to address unmet medical needs.
NYB Holdings Ltd operates an AI-first drug discovery and biotechnology platform that utilizes a large natural compound library and predictive modeling to identify bioactive compounds. The company develops science-backed wellness solutions for nutraceutical applications and advances high-potential drug candidates into preclinical development for the pharmaceutical industry.
Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.
Sharp Therapeutics Corp. is a preclinical-stage biotechnology and drug discovery company that develops small molecule therapies to treat genetic diseases and hereditary disorders. The company combines high-speed experimentation and computational methods to advance its drug discovery platform.
Daya CNS, LLC is a preclinical biopharmaceutical company that develops a proprietary non-opioid pyridoindole platform for the treatment of chronic pain, substance abuse disorders, and neuropsychiatric conditions. Its product pipeline includes small molecule medications such as DDD-028 for neuropathic and inflammatory pain, DDD-024 for addiction, and DDD-016 for neuropsychiatric disorders, serving patients with unmet medical needs in neurology and addiction medicine.
Get Mindset Pharma Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Mindset Pharma Inc. in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access